Articles

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Dana-Farber Cancer Institute, Boston, MA, USA
Division of Cardiovascular Medicine and Cardio-Oncology Program Vanderbilt School of Medicine, Nashville, TN, USA
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA
Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy
CA Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK
Hôpital Avicenne, AP-HP, UMR Paris13/INSERM U978, Bobigny, France
Mayo Clinic, Rochester, MN, USA
Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
Department of Haematology, Plymouth University Medical School, Plymouth, UK
Moores UCSD Cancer Center, San Diego, CA, USA
Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA, USA
Hôpital Haut-Lévêque, Bordeaux, Pessac, France
Department I of Internal Medicine and German CLL Study Group, University of Cologne, Germany
Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy
Medical University of Vienna, Austria
Department of Medicine III, Klinikum der Ludwig-Maximilians-Universität München, Campus Grosshadern, Germany
Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Janssen Research & Development, High Wycombe, UK
Janssen Research & Development, LLC, Raritan, NJ, USA
Janssen Research & Development, LLC, Leiden, the Netherlands
Pharmacyclics, Sunnyvale, CA, USA
Pharmacyclics, Sunnyvale, CA, USA
Pharmacyclics, Sunnyvale, CA, USA
Pharmacyclics, Sunnyvale, CA, USA
Janssen Research & Development, LLC, Raritan, NJ, USA
Janssen Research & Development, LLC, Raritan, NJ, USA
Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 102 No. 10 (2017): October, 2017 https://doi.org/10.3324/haematol.2017.171041